P2 purinergic receptors: Their regulation of bone metabolism and their therapeutic potential;P2-purinerge receptorer: Regulation af knogleomsætningen og terapeutisk potentiale?

Ugeskrift for Laeger

Volumn 167, Issue 34, 2005, Pages 3152-3156

  Solgaard, Marie ^a   Jørgensen, Niklas Rye ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOTIDE; PURINE P2 RECEPTOR; PURINE P2X RECEPTOR; PURINE P2Y RECEPTOR;

APOPTOSIS; BONE METABOLISM; BONE TURNOVER; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG TARGETING; HUMAN; METABOLIC REGULATION; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR UPREGULATION; REVIEW; BONE; BONE DEVELOPMENT; METABOLISM; OSTEOLYSIS; PHYSIOLOGY;

BONE AND BONES; BONE RESORPTION; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMANS; NUCLEOTIDES; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; RECEPTORS, PURINERGIC P2;

EID: 23844548402     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Burnstock G, Dumsday B, Smythe A. Atropine resistant excitation of the urinary bladder: the possibility of transmission via nerves releasing a purine nucleotide. Br J Pharmacol 1972;44:451-61.
2. Jorgensen NR, Henriksen Z, Sorensen OH et al. Intercellular calcium signaling occurs between human osteoblasts and osteoclasts and requires activation of osteoclast P2X7 receptors. J Biol Chem 2002;277:7574-80.
3. Jorgensen NR, Geist ST, Civitelli R et al. ATP- and gap junction-dependent intercellular calcium signaling in osteoblastic cells. J Cell Biol 1997;139:497-506.
4. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998;50:413-92.
5. Buell G, Collo G, Rassendren F. P2X receptors: an emerging channel family. Eur J Neurosci 1996;8:2221-8.
6. Jacobson KA, Jarvis MF, Williams M. Purine and pyrimidine (P2) receptors as drug targets. J Med Chem 2002;45:4057-93.
7. Harden TK, Boyer JL, Nicholas RA. P2-purinergic receptors: subtype-associated signaling responses and structure. Annu Rev Pharmacol Toxicol 1995;35:541-79.
8. Dubyak GR, el MC. Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Am J Physiol 1993;265:C577-606.
9. Bowler WB, Buckley KA, Gartland A et al. Extracellular nucleotide signaling: a mechanism for integrating local and systemic responses in the activation of bone remodeling. Bone, 2001;28:507-12.
10. Dixon SJ, Sims SM. P2 purinergic receptors on osteoblasts and osteoclasts: Potential targets for drug development. Drug Dev Res 2000;49:187-200.
11. Schofl C, Cuthbertson KS, Walsh CA et al. Evidence for P2-purinoceptors on human osteoblast-like cells. J Bone Miner Res 1992;7:485-91.
12. Boarder MR, Weisman GA, Turner JT et al. G protein-coupled P2 purinoceptors: from molecular biology to functional responses. Trends Pharmacol Sci 1995;16:133-9.
13. Maier R, Glatz A, Mosbacher J et al. Cloning of P2Y6 cDNAs and identification of a pseudogene: comparison of P2Y receptor subtype expression in bone and brain tissues. Biochem Biophys Res Commun 1997;240:298-302.
14. Nakamura E, Uezono Y, Narusawa K et al. ATP activates DNA synthesis by acting on P2X receptors in human osteoblast-like MG-63 cells. Am J Physiol Cell Physiol 2000;279:C510-9.
15. Dixon CJ, Bowler WB, Walsh CA et al. Effects of extracellular nucleotides on single cells and populations of human osteoblasts: contribution of cell heterogeneity to relative potencies. Br J Pharmacol 1997;120:777-80.
16. Buckley KA, Golding SL, Rice JM et al. Release and interconversion of P2 receptor agonists by human osteoblast-like cells. FASEB J 2003;17:1401-10.
17. Jones SJ, Gray C, Boyde A et al. Purinergic transmitters inhibit bone formation by cultured osteoblasts. Bone 1997;21:393-9.
18. Doty SB, Schofield BH. Metabolic and structural changes within osteocytes of rat bone. I: Talmage RV, Munson PL, eds. Calcium, parathyroid hormone and the calcitonins. Amsterdam: Excerptas Media, 1972:353-64.
19. Hoebertz A, Mahendran S, Burnstock G et al. ATP and UTP at low concentrations strongly inhibit bone formation by osteoblasts: a novel role for the P2Y2 receptor in bone remodeling. J Cell Biochem 2002;86:413-9.
20. Kaplan AD, Reimer WJ, Feldman RD et al. Extracellular nucleotides potentiate the cytosolic Ca2+, but not cyclic adenosine 3′,5′- monophosphate response to parathyroid hormone in rat osteoblastic cells. Endocrinology 1995;136:1674-85.
21. Jorgensen NR, Henriksen Z, Brot C et al. Human osteoblastic cells propagate intercellular calcium signals by two different mechanisms. J Bone Miner Res 2000;15:1024-32.
22. Buckley KA, Hipskind RA, Gartland A et al. Adenosine triphosphate stimulates human osteoclast activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-kappaB ligand. Bone 2002;31:582-90.
23. Morrison MS, Turin L, King BF et al. ATP is a potent stimulator of the activation and formation of rodent osteoclasts. J Physiol 1998;511:495-500.
24. Steinberg TH, Jorgensen NR, Bong JS et al. P2-mediated responses in osteoclasts and osteoclast-like cells. Drug Dev Res 2000;49.
25. Rabadjija L, Brown EM, Swartz SL et al. H(+)-stimulated release of prostaglandin E2 and cyclic adenosine 3′,5′-monophosphoric acid and their relationship to bone resorption in neonatal mouse calvaria cultures. Bone Miner 1990;11:295-304.
26. Chiozzi P, Sanz JM, Ferrari D et al. Spontaneous cell fusion in macrophage cultures expressing high levels of the P2Z/P2X7 receptor (published erratum appears in J Cell Biol 1997 Oct 20;139:following 571). J Cell Biol 1997;138:697-706.
27. Murgia M, Pizzo P, Steinberg TH et al. Characterization of the cytotoxic effect of extracellular ATP in J774 mouse macrophages. Biochem J 1992;288:897-901.
28. Ke HZ, Qi H, Weidema AF et al. Deletion of the P2X7 nucleotide receptor reveals its regulatory roles in bone formation and resorption. Mol Endocrinol 2003;17:1356-67.
29. Walther MM, Kragel PJ, Trahan E et al. Suramin inhibits bone resorption and reduces osteoblast number in a neonatal mouse calvarial bone resorption assay. Endocrinology 1992;131:2263-70.
30. Farsoudi KH, Pietschmann P, Cross HS et al. Suramin is a potent inhibitor of calcemic hormone- and growth factor-induced bone resorption in vitro. J Pharmacol Exp Ther 1993;264:579-83.
31. Yoneda T, Williams P, Rhine C et al. Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer. Cancer Res 1995;55:1989-93.